GlassScriptPhysician profile
Thomas R Arndt
NPI 1487614210
$5,341.76
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,317 · 2020: $1,341 · 2021: $306 · 2022: $300 · 2023: $1,030 · 2024: $47.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,909.83 | 2019-2020 | |
| Abbvie INC. | $695.27 | 2019-2024 | Skyrizi, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $303.13 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $256.49 | 2019-2023 | Stelara |
| Janssen Scientific Affairs, LLC | $194.16 | 2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $172.65 | 2019-2024 | Entyvio |
| Echosens North America, INC. | $139.54 | 2023 | Fibroscan |
| Endogastric Solutions, INC | $107.85 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $100.89 | 2022 | |
| Pfizer INC. | $66.86 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $65.60 | 2019 | |
| Ardelyx, INC. | $54.29 | 2022-2023 | Ibsrela |
| Celgene Corporation | $42.17 | 2021-2023 | Zeposia |
| Mauna Kea Technologies, INC. | $28.58 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.54 | 2023 | Cyltezo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $20.61 | 2019 | |
| Shionogi INC | $19.87 | 2019 | |
| Redhill Biopharma INC. | $18.15 | 2020 | |
| Vivus LLC | $17.68 | 2023 | Pancreaze |
| Braintree Laboratories, INC. | $17.21 | 2023 | Suflave |
| Merck Sharp & Dohme LLC | $17.09 | 2023 | Dificid |
| W. L. Gore & Associates, INC. | $15.12 | 2023 | Gore Cardioform Septal Occluder |
| Amgen INC. | $14.94 | 2023 | Amjevita |
| Evoke Pharma, INC. | $14.43 | 2023 | Gimoti |
| Shire North American Group INC | $13.44 | 2019 | |
| Medtronic, INC. | $12.37 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,636.60 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Arndt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.